Background: Echinococcosis is a parasitic zoonosis that predominantly affects the liver and pulmonary system. Isolated involvement of skeletal muscle in the absence of visceral disease is exceptionally rare, accounting for approximately 1-3% of cases. Owing to nonspecific clinical manifestations and overlapping imaging characteristics, muscular hydatid cysts may be misinterpreted as neoplastic lesions or abscesses, thereby complicating the diagnostic process. Case Report: A 64-year-old woman presented with a painful mass in the posterior aspect of her thigh that had gradually increased in size. Magnetic resonance imaging revealed a well-circumscribed cystic lesion containing detached internal membranes, consistent with World Health Organization (WHO) stage 3a cystic echinococcosis (CE3a) and indicative of an active transitional hydatid cyst. Serological testing was strongly positive, and no evidence of hepatic or pulmonary involvement was detected. The patient was treated with albendazole therapy followed by a percutaneous puncture-aspiration-injection-reaspiration (PAIR) procedure, resulting in cyst regression without complications. Conclusion: In endemic regions, hydatid disease should be considered in the differential diagnosis of atypical soft-tissue masses, even in the absence of visceral organ involvement or a clear history of exposure.
Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer in adults. It is also one of the most aggressive tumors of the central nervous system and is associated with the worst prognosis. Developing an effective treatment method is complicated by the disease: its resistance to treatment, a high recurrence rate, and genetic and histological heterogeneity. This review provides a detailed assessment of GBM diagnostic methods, molecular pathogenesis, histopathological features, and current treatment approaches. IDH mutations, together with molecular markers such as PTEN, EGFR, TP53, and MGMT promoter methylation, play a significant role in predicting the course of glioblastoma multiforme and determining treatment response. Personalized medicine and immunotherapies, together with routine treatments, represent noteworthy approaches to GBM treatment in the near future. Recent studies report that magnetic field-based interventions are a promising approach and that applications of low-frequency magnetic fields suppress glioma cell proliferation. Studies conducted with the OM-100 device have shown a significant reduction in tumor growth in both in vivo and in vitro models and have demonstrated synergistic effects when the device was combined with anti-PD-1 therapy. Furthermore, static magnetic fields have been reported to increase apoptosis, inhibit proliferation, and may offer a complementary treatment with low toxicity. These findings suggest that magnetic-field-based approaches offer an innovative strategy for GBM treatment.
Background: Schwannoma is a rare, slow-growing nerve sheath tumor that is infrequently reported in the anterior chest wall and requires thorough evaluation for accurate identification and appropriate treatment. Case Report: We describe a case of a 57-year-old woman with an incidentally discovered parasternal ancient schwannoma of the anterior chest wall during breast cancer screening. Contrast-enhanced computed tomography (CT) revealed a well-defined soft tissue mass located in the right third intercostal space. Surgical excision was performed via right anterior thoracotomy. Histopathological examination confirmed the diagnosis of ancient schwannoma. The patient experienced an eventful postoperative recovery, with no recurrence observed during two years of follow-up. Conclusion: Anterior chest wall schwannomas are rare incidental findings. Accurate imaging and complete surgical excision are essential for diagnosis and management, ensuring favorable outcomes and highlighting the importance of timely recognition of these uncommon tumors.
Objective:This study aimed to determine the effect of non-invasive hemoglobin (SpHb) measurement on blood transfusion decisions in patients undergoing hip surgery and to analyze the effect of these decisions on mortality. Materials and Methods:Fifty-two patients (ASA I-III, ≥60 years) undergoing hip surgery were randomized into the SpHb or conventional (CONV) group for transfusion management. Hemoglobin (Hb) levels were recorded before induction, at transfusion decision points, immediately after transfusion, and after recovery. Postoperative survival was monitored at 1 and 3 months. Results:The SpHb group maintained significantly higher Hb levels at the first transfusion decision point, after transfusion, and during recovery (p=0.001, p=0.012, p=0.001). Partial oxygen pressure (PaO2) was also higher in the SpHb group at the corresponding time points. The CONV group required significantly more blood transfusions (p=0.025) and had longer hospital stays (p=0.043). Although 3-month mortality was numerically lower in the SpHb group than in the CONV group (11.53% vs. 19.23%), no statistically significant difference was detected in this pilot-sized cohort (p>0.05). Conclusion:According to our findings, SpHb monitoring during hip surgery may be a useful tool for enabling earlier transfusion decisions, which could help prevent significant Hb declines. In our study cohort, this strategy was associated with a trend toward fewer transfusion requirements, shorter hospital stays, and better perioperative oxygenation.
A retrospective study was conducted to evaluate the need for perioperative autotransfusions and the amount of blood loss by comparing patients receiving different tranexamic acid (TXA) regimens following total joint replacement (TJR). A total of 1675 patients undergoing TJR were included: 76 did not receive TXA administration (group A); 77 received IV TXA (group B); 1510 received IV followed by IA administration of TXA (group C); and 12 received IA TXA administration alone (group D). Significant between-group differences were observed in intraoperative and postoperative blood loss (p<0.05). Blood autotransfusion and allogeneic transfusion rates were significantly higher in group D compared with the other treatment strategies (p<0.001) and with the control group of patients who did not receive TXA (p<0.05). IV combined with IA TXA administration represents the most effective way to prevent blood loss following TJA surgery. Conversely, isolated IA administration of TXA did not reduce the need for postoperative transfusions.
